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We previously identiﬁed the NS5A/HSP70 binding site to be a hairpin moiety at C-terminus of NS5A
domain I and showed a corresponding cyclized polyarginine-tagged synthetic peptide (HCV4) signiﬁ-
cantly blocks virus production. Here, sequence comparison conﬁrmed ﬁve residues to be conserved.
Based on NS5A domain I crystal structure, Phe171, Val173, and Tyr178 were predicted to form the
binding interface. Substitution of Phe171 and Val173 with more hydrophobic unusual amino acids
improved peptide antiviral activity and HSP70 binding, while similar substitutions at Tyr178 had a
negative effect. Substitution of non-conserved residues with arginines maintained antiviral activity and
HSP70 binding and dispensed with polyarginine tag for cellular entry. Peptide cyclization improved
antiviral activity and HSP70 binding. The cyclic retro-inverso analog displayed the best antiviral
properties. FTIR spectroscopy conﬁrmed a secondary structure consisting of an N-terminal beta-sheet
followed by a turn and a C-terminal beta-sheet. These peptides constitute a new class of anti-HCV
compounds.
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Introduction
The hepatitis C virus (HCV) infects 3% of the world population
and is mainly responsible for liver transplantation in patients with
cirrhosis in developed countries (Shepard et al., 2005). Further-
more, HCV is the most common chronic blood borne pathogen in
the United States (U.S.) affecting 1.8% of the population and is the
major etiologic factor responsible for the recent doubling of
hepatocellular carcinoma (HCC) (El-Serag, 2002).
Recently HCV infection has been treated with a combination of
pegylated interferon-α (PEG-IFN), ribavirin (RBV) and NS3/4A protease
inhibitors which have improved sustained virological response (SVR)
from PEG-IFN and RBV alone, but also increased adverse side effects
including anemia and gastrointestinal symptoms (Ciesek and Manns,
2011). In December of 2013 sofosbuvir which targets the viral poly-
merase was FDA approved in combination with PEG-IFN and RBV and
showed very high efﬁcacy (at least 90% in clinical trials) but at great
cost $84,000–$168,000. Efﬁcacy and adverse events outside clinical
trials remain to be evaluated. There is optimism that a combination of
direct acting antivirals (DAAs) may eliminate the need for PEG-IFN and
RBV, the major culprits responsible for signiﬁcant side effects. How-
ever, DAAs can result in resistant virus as targeting viral proteins puts
direct selective pressure for resistant mutants. Therefore, there is still a
need for new compounds to use in drug cocktails to improve efﬁcacy,
avert resistance, reduce cost, and reduce adverse events.
HCV is an RNA virus classiﬁed in the genus Hepacivirus in the
Flaviviridae family. It possesses an approximately 9.6 kb positive sense
RNA genome that is translated as a single polypeptide approximately
3000 amino acids in length (Baron, 1996; Lindenbach and Rice, 2005).
It is subsequently proteolytically cleaved into 10 viral proteins includ-
ing the structural proteins Core, E1, E2, and the integral membrane ion
channel p7, as well as the non-structural (NS) proteins NS2, NS3,
NS4A, NS4B, NS5A and NS5B (Lindenbach and Rice, 2005). The 50 non-
coding region (NCR) of the viral genome possesses an internal
ribosomal entry site (IRES) (Wang et al., 1993), a cis-acting element
found in some host RNA transcripts as well as in viruses that allows
ribosomal translation initiation to occur internally within a transcript
in lieu of 50 cap dependent translation (Pacheco and Martinez-Salas,
2010). The HCV viral life cycle in a cell can be divided into six phases:
1) binding and internalization, 2) cytoplasmic release and uncoating,
3) viral polyprotein translation and processing, 4) RNA genome
replication, 5) packaging and assembly, and 6) virus morphogenesis
and secretion (Moradpour et al., 2007). NS5A, a 56–59 kDa multi-
functional phosphoprotein, is a component of the viral replicase
complex and has been implicated in regulation of HCV genome
replication, IRES-mediated viral protein translation, virion assembly,
and infectious virion secretion (He et al., 2003; Hughes et al., 2009;
Khachatoorian et al., 2012a, 2012b; Tellinghuisen et al., 2008).
Interestingly, cellular heat-shock proteins (HSPs) also play an
important role in the replication of RNA viruses (Vasconcelos et al.,
1998; Weeks and Miller, 2008; Zheng et al., 2010). HSPs, which
normally assist unfolded or mis-folded polypeptide chains to (re)
fold into functional proteins, are crucial for cell survival during
stressful conditions (Mayer and Bukau, 2005). We have previously
identiﬁed, through co-immunoprecipitation and subsequent mass
spectrometric analyses, an NS5A/HSP complex composed of NS5A,
HSP70, and HSP40 (cofactor of HSP70) and demonstrated their
co-localization in Huh-7 cells (Gonzalez et al., 2009). We further
showed that both NS5A-augmented IRES-mediated translation
and virus production are blocked by 1) HSP70 knockdown, 2)
the HSP synthesis inhibitor quercetin, a bioﬂavonoid, and 3) a
small hairpin peptide (HCV4) from NS5A domain I that is capable
of blocking NS5A/HSP70 interaction, with no associated cytotoxi-
city (Gonzalez et al., 2009; Khachatoorian et al., 2012a, 2012b).
These ﬁndings support our hypothesis that HCV utilizes an NS5A/
HSP complex for the IRES-mediated translation of its genome.
The HCV4 hairpin peptide described previously (Khachatoorian
et al., 2012b) is a potent small molecule inhibitor of virus speciﬁc
NS5A-driven IRES-mediated translation of the viral genome and is
also capable of disrupting the NS5A/HSP70 complex formation
in vitro. This peptide was identiﬁed by deletion analyses of NS5A
which narrowed down the site of NS5A/HSP70 interaction to the C
terminal 34 amino acids of NS5A domain I (C34) followed by
alanine scanning mutagenesis on the C34 region. These analyses
identiﬁed the NS5A/HSP70 binding region on NS5A to be the
hairpin moiety at C34 hereafter referred to as the HSP binding
domain (HBD). Subsequently, we sought to further characterize
the HBD site and identify the speciﬁc amino acid residues involved
in this interaction, with the goal of generating peptides that would
be even more potent than the HCV4 analog. We refer to these
peptides as HSP interfering peptides (HIPs).
Results
Five amino acid residues are conserved in the HSP binding domain
(HBD) of NS5A
HBD consists of 10 amino acids that form a beta-sheet structure
at the C terminus of NS5A domain I (Fig. 1). Comparison of the H77
and Con1 sequences at the site of HBD revealed ﬁve conserved
residues: Phe171, Val173, Gly174, Leu175, and Tyr178 (Table 1,
highlighted in green). We hypothesized that these ﬁve residues
may be critical for the NS5A/HSP70 interaction.
A structural analysis of the hairpin region in the crystal structure
of dimeric NS5A domain I (Tellinghuisen et al., 2005) revealed that
Phe171, Val173, and Tyr178 occur within and on one side of the plane
of the two beta-sheets, while Leu175 extends on the opposite face
and is located on the linker region between the two beta-sheets
(Fig. 1). The spatial orientation of Phe171, Val173, and Tyr178
supports their role in forming a binding interface that interacts with
Fig. 1. Schematic representation of the HBD region (green) based on the previously
reported crystal structure of dimeric NS5A domain I (Tellinghuisen et al., 2005).
(A) NS5A domain I dimer. (B) The HBD hairpin moiety shown at two different
angles. The side chains of four conserved residues (Phe171, Val173, Leu175, and
Tyr178) are also shown. (C) The HBD hairpin moiety showing four additional
residues in blue (Thr170, Leu172, Gln177 and Leu179) that were substituted with
arginine residues to enhance cell permeability of HCV peptides.
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HSP70. We reasoned that Gly174 and Leu175 are necessary for a turn
between the two beta-sheets of the hairpin and may, therefore, play
a stabilizing role in the NS5A/HSP70 interaction consistent with the
role of glycine and leucine in facilitating beta-turns.
Based on these observations, we hypothesized that Phe171,
Val173, and Tyr178 form the main binding motif and that certain
substitutions (e.g. more hydrophobic) in these positions might affect
peptide antiviral activity. Through computer assisted molecular
modeling, we also reasoned that Gly174 may be substituted with
D-Pro to facilitate a turn between the hairpin's two beta-sheets in
order to help maintaining a hairpin-like structure. Thus, all the
peptides generated for this study bear D-Pro instead of Gly at position
174 (except for the retro-inverso analog HCV18RI which bears an L-Pro
at this position) (Table 1). Also Leu175 was substituted with the more
hydrophobic cyclohexylalanine (Cha) (Table 1).
We proceeded to generate groups of peptide derivatives of HCV4
with different modiﬁcations as described below, and all peptides
were tested for their antiviral activity. Representative peptides from
each group were further assayed to determine their dose response
as well as HSP70 binding afﬁnity. HCV1-3 were not tested for their
antiviral activity in this study as they do not possess an arginine tag
or a sufﬁcient number of internal arginine residues and would,
therefore, be incapable of cellular entry. However, we have pre-
viously reported an effective liposome-mediated delivery of HCV2
and HCV3 (Khachatoorian et al., 2012b). HCV1–3 were, nonetheless,
tested for their structural conformation.
Substitution of Phe171 and Val173 with more hydrophobic residues
increases peptide antiviral activity and HSP70 binding afﬁnity
Based on the spatial arrangement of the Phe171, Val173, and
Tyr178 residues, we hypothesized that substitutions within the
synthetic hairpin peptides at these residues would affect their
binding to HSP70 and, therefore, alter the antiviral activity of these
peptides. All amino acid substitutions used were intended to
increase the hydrophobicity of these residues as they possess
larger hydrophobic side chains. To this end, we used L-2-naphthy-
lalanine (2Nal) and L-3,30-diphenylalanine (Dpa) as substituents for
Phe171 and L-cyclohexylglycine (Chg) and S-tert-butyl-L-cysteine
(CystBu) as substituents for Val173. All peptides bearing any of
these modiﬁcations at Phe171 and/or Val173 are marked with the
solid triangle symbol ▲ in Tables 1–3 and Fig. 2. HCV9, HCV10,
HCV11, HCV12, HCV15, and HCV18 indeed showed improved
antiviral activity compared with the HCV4 peptide in the HCV cell
culture (HCVcc) system (Fig. 2A).
We also determined the dose response of HCV10, HCV15, and
HCV18 and showed that the IC50 of these peptides is lower compared
with HCV4 (Table 2). In addition, we determined the HSP70 binding
afﬁnity of these peptides through surface plasmon resonance (SPR)
analyses utilizing recombinant full-length HSP70 in fusion with
N-terminal maltose binding protein (MBP) immobilized on the SPR
chip. The HSP70 binding afﬁnity of HCV10, HCV15, and HCV18 was
found to be higher than that of HCV4 (Table 3).
Substitution of Tyr178 with more hydrophobic residues decreases
peptide antiviral activity and HSP70 binding afﬁnity
Tyr178 is a polar residue, and we hypothesized that substitut-
ing it with highly hydrophobic residues may impair the antiviral
activity of the peptides. We utilized L-4,40-biphenylalanine (Bip) or
L-Dpa as substituents for Tyr178, and peptides bearing these
modiﬁcations at Tyr178 are marked with the open triangle symbol
△. As shown in Fig. 2A, these analogs (HCV7, HCV8, HCV13, and
HCV14) showed decreased efﬁcacy in blocking virus production in
Table 1
Sequence and characterization of all peptides generated. The green highlights indicate the conserved amino acids. The red highlights indicate amino acid substitutions that
resulted in peptides with better efﬁcacy at blocking HCV proliferation and higher HSP70 binding afﬁnity compared to HCV4, while the blue highlights indicate lower antiviral
activity and HSP70 binding afﬁnity. Cyclization of the peptides is also emphasized by gray highlights at both the N and C termini. The symbols to left of the table refer to
speciﬁc modiﬁcations to peptides: ▲ indicates substitution of Phe171 and/or Val173 with more hydrophobic residues; △ indicates substitution of Tyr178 with more
hydrophobic residues; ■ indicates addition of a lipid tag to the peptide; n indicates the retro-inverso analog; ♢ indicates peptide linearization; and □ indicates decreasing the
length of cyclizing linker achieved by a thioether linkage. Solid symbols indicate a beneﬁcial modiﬁcation (i.e. improved antiviral activity and HSP70 binding), while open
symbols indicate a negative effect. (2Nal¼2-naphthylalanine; -Ac¼acetyl group; Ahx¼6-aminohexanoic acid; Bip¼L-4,40-biphenylalanine; Cha¼cyclohexylalanine;
Chg¼cyclohexylglycine; CysSH¼reduced cysteine; CystBu¼S-tert-butyl-L-cysteine; Dpa¼L-3,30-diphenylalanine; Pal¼palmitoic acid).
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comparison with the HCV4 peptide. The dose response of HCV14
which bears the Tyr178Bip substitution (IC5031 nM) was also
much lower compared with HCV4 (IC500.452 nM) (Table 2).
Furthermore, SPR analyses demonstrated that the HSP70 binding
afﬁnity of HCV14 decreased compared with HCV4 (Table 3).
Substitution of the non-conserved amino acids with arginines enables
membrane penetration without a polyarginine tag and maintains
peptide antiviral activity
The HCV4 peptide consists of a polyarginine tag at its N-terminus
which allows for cellular internalization (Table 1). Addition of this tag
signiﬁcantly increases the molecular weight of the peptide and may
lead to cellular toxicity. The two beta-sheets of the hairpin structure
include ﬁve non-conserved residues: Thr170, Leu172, Asn176, Gln177,
and Leu179 (Table 1). We hypothesized that these non-conserved
residues can be substituted with arginines without signiﬁcantly
altering the antiviral activity of the peptides, and we substituted
Thr170, Leu172, Gln177, and Leu179 with arginines (Fig. 1C, blue
residues). As shown in Fig. 2A, peptides bearing arginines at these
positions (HCV5-HCV15, HCV15R, HCV16, HCV18, and HCV18RI)
maintained their antiviral activity compared to the HCV4 peptide,
which indicates that they were capable of penetrating the plasma
membrane. Furthermore, these peptides have the beneﬁt of being
signiﬁcantly smaller. All the peptides in this study were generated
without the polyarginine tag.
Addition of a lipid tag to the peptide does not interfere with its
antiviral activity
We also sought to determine whether conjugation of a lipid
(e.g. palmitic acid) to the HCV5 peptide would interfere with its
Fig. 2. Antiviral activity of peptides and their cytotoxicity proﬁle. (A) Antiviral
activity of peptides. Intracellular virus production assay was performed on cells
treated with the indicated peptides at a concentration of 10 nM. The y axis reﬂects
relative Renilla luciferase levels. (B) Dose response of peptides. Intracellular virus
production assay was performed on cells treated with the indicated peptides at a
concentration range of 0.001–1000 nM. The y axis reﬂects relative Renilla luciferase
levels. (C) Peptides are not cytotoxic. MTT assay was performed on cells treated
with 10 nM–10 mM of indicated peptides. Assay was performed every 24–72 h after
treatment. The data for 10 mM and 72 h treatment is shown. The symbols in panels
A and B refer to speciﬁc modiﬁcations to peptides: ▲ indicates substitution of
Phe171 and/or Val173 with more hydrophobic residues; △ indicates substitution of
Tyr178 with more hydrophobic residues; ■ indicates addition of a lipid tag to the
peptide; n indicates the retro-inverso analog; ♢ indicates peptide linearization; and
□ indicates decreasing the length of cyclizing linker achieved by a thioether linkage.
Solid symbols indicate a beneﬁcial modiﬁcation (i.e. improved antiviral activity and
HSP70 binding), while open symbols indicate a negative effect.
Table 2
The IC50 values for the indicated peptides. Intracellular virus production assay was
performed on cells treated with the indicated peptides at a concentration range of
0.001–1000 nM. The symbols to left of the table refer to speciﬁc modiﬁcations to
peptides: ▲ indicates substitution of Phe171 and/or Val173 with more hydrophobic
residues; △ indicates substitution of Tyr178 with more hydrophobic residues; n
indicates the retro-inverso analog; ♢ indicates peptide linearization; and □ indicates
decreasing the length of cyclizing linker achieved by a thioether linkage. Solid
symbols indicate a beneﬁcial modiﬁcation (i.e. improved antiviral activity and
HSP70 binding), while open symbols indicate a negative effect.
Table 3
The dissociation constants for the indicated peptides. Constants were calculated
using SPR assays conducted by injecting the indicated peptides at different
concentrations onto the HSP70-bound chip. The symbols to left of the table refer
to speciﬁc modiﬁcations to peptides: ▲ indicates substitution of Phe171 and/or
Val173 with more hydrophobic residues; △ indicates substitution of Tyr178 with
more hydrophobic residues; n indicates the retro-inverso analog; ♢ indicates
peptide linearization; and □ indicates decreasing the length of cyclizing linker
achieved by a thioether linkage. Solid symbols indicate a beneﬁcial modiﬁcation
(i.e. improved antiviral activity and HSP70 binding), while open symbols indicate a
negative effect.
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antiviral activity, as lipidation may be beneﬁcial for in vivo studies
(targeting the peptide to the liver and increasing the plasma half-
life). Therefore, we generated the HCV6 peptide (Table 1), the
palmitoylated analog of HCV5 (marked with the solid square
symbol ■), and demonstrated that its antiviral activity is compar-
able to that of HCV5 (Table 1 and Fig. 2A).
The retro-inverso form of the hairpin peptide maintains its antiviral
activity and HSP70 binding afﬁnity
As peptides are subjected to degradation in the intracellular
environment and in vivo, we sought to determine whether the
retro-inverso form of the hairpin peptide would be feasible in
terms of antiviral activity. We generated a retro-inverso analog of
HCV18 (HCV18RI) where the peptide was synthesized in reverse
order and all the L-amino acids were substituted with their
D-counterparts, while the D-Pro174 was changed to L-Pro. HCV18RI
is represented with the star n symbol. In comparison with HCV18,
HCV18RI maintained antiviral activity (Fig. 2A), dose response
(Fig. 2B and Table 2), and HSP70 binding afﬁnity (Table 3).
Cyclization of the peptides improves their antiviral activity
We reasoned that the characteristic anti-parallel beta-sheet
structure of the HBD hairpin may be important for the antiviral
activity of the analog peptides. Therefore, we generated the
HCV15R peptide, represented with the open diamond ♢ symbol,
which is linear due to the reduced disulﬁde bond that cyclizes the
peptide (Table 1). As shown in Fig. 2A, linearization of the peptide
reduced its antiviral activity with the cyclized form being more
effective than the linear form. Furthermore, the dose response of
HCV15R (IC503 nM) was signiﬁcantly reduced compared to
HCV15 (IC500.192 nM) (Fig. 2B and Table 2). Linearization of
the peptide also decreased the binding afﬁnity of HCV15R to
HSP70 compared with HCV15 and HCV4 (Table 3).
Linearization of the peptide may reduce the efﬁcacy of the peptide
by eliminating the optimal hairpin-like conformation of the peptide
and/or decreasing its half-life as linear peptides may be more
susceptible to enzymatic degradation. We synthesized all peptide
analogs used in this study (except HCV15R) with a cyclizing linker.
Decreasing the length of the cyclizing linker in peptides lowers their
antiviral activity
The majority of the peptide analogs used in this study were
cyclized by a disulﬁde linker to achieve the hairpin-like structural
conformation observed in the crystal structure (Tellinghuisen
et al., 2005) (Fig. 1). To determine if altering the length of the
linker would affect the efﬁcacy of the peptide, we synthesized an
analog of the HCV15 peptide (HCV16, marked with the open
square ♢ symbol) in which the disulﬁde linker is replaced by the
shorter S-carboxymethyl-linker, obtained by substituting the N-
terminal cysteine with a chloroacetyl group and subsequent
intramolecular S-alkylation (Table 1). Decreasing the linker length
negatively impacted the antiviral efﬁcacy of the peptide (Fig. 2A).
The IC50 of the peptide also increased from 0.192 nM (HCV15) to
0.345 nM (HCV16) (Table 2). This may indicate that the binding of
the HBD hairpin is highly optimized in the binding pocket and that
minute structural changes may affect its conformation effectively
decreasing the peptide binding afﬁnity. Thus, we tested the HSP70
binding afﬁnity of HCV16 and found that its dissociation constant
was higher than that of HCV15 (Table 3).
Hairpin peptide analogs do not display cytotoxic effects
To ensure that the antiviral activity of the peptides in the
HCVcc system is not affected by their potential cytotoxic effects,
MTT assays were performed at a concentration range of 10 nM–
10 mM for 72 h of treatment. As shown in Fig. 2C, no signiﬁcant
cytotoxicity was observed at the 10 mM concentration after 72 h of
peptide treatment.
Secondary structure analysis of HCV peptides by Fourier transform
infrared (FTIR) spectroscopy demonstrates a predominant beta-sheet
structure
We proceeded to determine the secondary structure of the HCV
suite of peptides in aqueous solvent systems using FTIR spectroscopy.
The results of FTIR spectral analyses are shown in Fig. 3A and B, and
the results of the deconvolution of the spectra are shown in Table 4. In
aqueous buffer, all of the HCV peptides have a dominant beta-sheet
structure (Table 4). The parental peptide HCV1 has a secondary
structure in aqueous buffer that is anti-parallel beta-sheet with a
major peek centered around 1625 cm1 and a minor signature band
at 1690 cm1 (Fig. 3A) that is similar to the conformation observed in
the crystal structure of NS5A domain I (Tellinghuisen et al., 2005). In
contrast to the spectrum of HCV1, all other HCV variants have a
broader spectrum centered from 1630 to 1638 cm1, and that is more
typical of peptides assuming mostly parallel beta-sheet conformations
(Fig. 3A and B). Overall, the deconvolution results suggest that all
peptides have largely beta-sheet structure followed by turn and
disordered conformations in aqueous environments. There were only
minor contributions for alpha helical conformations with the most
notable amount for the reduced form of the peptide (HCV15R)
(Table 4). Further, the contribution of turns is lowest for HCV15R.
These observations are consistent with our ﬁndings above that the
HCV15R peptide (with reduced disulﬁde bond) displays a signiﬁcant
decrease in antiviral activity and HSP70 binding afﬁnity (Fig. 2A and
Tables 2 and 3).
13C-enhanced FTIR spectroscopy of HCV3 peptide indicates a
secondary structure consisting of an N terminal beta-sheet followed
by a turn and a C terminal beta-sheet
To gain further insights into the residue speciﬁc structure of the
HCV variants, we isotopically enhanced HCV3 residues with 13C
carbonyl labels for selective amino acids in the N-terminal, mid-
sequence, and C-terminal domains (Dwivedi and Krimm, 1984;
Tadesse et al., 1991). The spectra for the selectively labeled sequences
are shown in Fig. 3C. When HCV3 peptide was enhanced with 13C
labels at Phe at position 3 (Phe171) and Val at position 5 (Val173),
there was a characteristic shift of 37 wavenumbers from 1635 cm1 to
1598 cm1 indicative of these residues assuming parallel beta-sheet
conformations (Fig. 3C, spectrumHCV3a). Spectra of themid-sequence
13C carbonyl labels at Gly at position 6 (Gly174) and Leu at position 7
(Leu175) also showed a spectral down shift from 1649 cm1 to
1612 cm1 typical of residues participating in Type III beta-turn (310
helix) conformations when in deuterated buffer (Byler and Susi, 1986)
(Fig. 3C, spectrum HCV3b). When the Tyr at position 10 (Tyr178) was
enhanced with 13C, there was also a shift from the beta-sheet region of
the unlabeled parent FTIR spectra centered in the 1632 cm1 absor-
bance to 1695 cm1 suggesting that this residue was also assuming
mostly parallel beta-sheet conformations (Fig. 3C, spectrum HCV3c).
Molecular simulation conﬁrms a beta-hairpin secondary structure for
HCV3 peptide
Based on the above 13C labeled residue assignments obtained
by isotope enhanced FTIR measurements, a highly accurate model
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of HCV3 in water was then determined using molecular dynamics
reﬁnement. This was facilitated by conformationally constraining
the labeled residue while allowing the remaining residues to
assume conformations indicative of an equilibrium conformation
in a simulated water environment. As shown in Fig. 4A and B, the
HCV3 peptide backbone rapidly reached a stable equilibrium
secondary conformation within the ﬁrst few nanoseconds of
simulation. Based on the molecular dynamics reﬁnement, the
residue speciﬁc secondary structure of HCV3 is diagramed in
Fig. 4C. The sequential map indicates that the disulﬁde linked
Cys1 and Cys12 have a random or disordered conformation while
the beta-sheet components ﬂank a well-deﬁned turn element that
includes Gly6 and Leu7. There are two beta-sheet components one
from Ser2 to Val5 and the other from His8 to Pro11. The beta-
sheets assume mostly parallel conformations and are conﬁgured
with the turn to form a beta-hairpin structure (Fig. 5A) which is
remarkably similar to the HBD moiety from the crystal structure
(Tellinghuisen et al., 2005) (Fig. 5B). This overall structure has an
amphipathic character with amino acids on one side of the beta-
hairpin being polar residues and the other side bearing amino
acids with hydrophobic side chains. There are also two intra-chain
components that stabilize the parallel beta-hairpin format along
with the disulﬁde linkage between Cys1 and Cys12. One element is
the salt bridge between Arg4 and Glu9. The existence of this ion-
lock is conﬁrmed by the fact that the distance between the side-
chain charged group centroids is maintained during the simulation
to be within the 4 angstrom distance typical of most salt-bridges
in proteins (Kumar and Nussinov, 1999). A second non-covalent
side chain interaction that potentially adds to the stability of the
Fig. 3. FTIR spectroscopy analyses of HCV peptides. (A, B) FTIR spectral analysis of unlabeled HCV peptide secondary structure in deuterated 10 mM phosphate buffer pD 5.6.
(C) FTIR spectral analysis of HCV3 13C isotope enhanced peptide secondary structure in deuterated 10 mM phosphate buffer pD 5.6. HCV3 is unlabeled peptide; HCV3a is
isotopically enhanced at residues Phe3 and Val5; HCV3b is isotopically enhanced at Gly6 and Leu7; and HCV3c is isotopically enhanced at Tyr10.
Table 4
Proportions of secondary structurea for HCV peptidesb in deuterated phosphate
buffer as estimated from Fourier self-deconvolution of the FTIR spectrac of the
peptide amide I band.
Peptide % Conformation
α-Helix β-Sheet Turn Disordered
HCV1 2.10 43.11 31.05 23.74
HCV2 4.66 53.56 28.94 17.84
HCV3 11.60 54.34 21.96 12.04
HCV4 11.86 41.48 29.21 17.45
HCV5 10.55 50.90 25.72 12.83
HCV6 12.34 52.87 20.39 14.40
HCV15 11.05 39.52 31.46 17.97
HCV15R 24.77 49.12 12.97 13.14
HCV16 14.68 40.36 18.71 26.25
HCV18 5.88 47.91 29.74 16.47
HCV18RI 7.82 53.88 22.55 15.75
a Data are the means of four separate determinations and have an SE75% or
better.
b HCV Peptide [i.e., 2 mM HCV] desolvated in deuterated 10 mM phosphate
buffer pD 5.6 (Fig. 3).
c FTIR spectra were deconvoluted as described in Materials and methods.
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beta-hairpin structure is the interaction between Phe3 and Tyr10.
This Phe-Tyr aromatic pair maintains Cα–Cα distances over the
time course of the molecular dynamics run that favor π-stacking
and T-shape orientations for possible interactions that enhance
intra-chain stability of the hair-pin structure (Chelli et al., 2002;
McGaughey et al., 1998).
Discussion
In this study, we have characterized the interaction of the NS5A
HBD with HSP70, identiﬁed the amino acid residues involved in the
NS5A/HSP70 interaction, and developed peptides that are more
efﬁcacious than HCV4 in binding HSP70 and in blocking virus
production.
As reported previously, the HBD-mediated NS5A/HSP70 inter-
action is involved in the NS5A-driven IRES-mediated translation of
the viral genome, and treatment of cells with the peptides
corresponding to HBD signiﬁcantly inhibits IRES-mediated trans-
lation (Khachatoorian et al., 2012b). Furthermore, knockdown of
HSP70 was shown by our group and others to signiﬁcantly reduce
viral IRES-mediated translation and protein production (Gonzalez
et al., 2009; Lim et al., 2012). These and our current results indicate
that the NS5A/HSP70 interaction is critical for viral proliferation.
Recently, we also analyzed the binding of heat shock cognate
protein (HSC) 70 with NS5A and found that NS5A and HSC70
directly bind each other as well (Khachatoorian et al., 2014).
Nonetheless, our data as well as another report indicated that
HSC70 is involved in infectious virion assembly rather than IRES-
mediated translation (Khachatoorian et al., 2014; Parent et al.,
2009). We also showed that the compensatory upregulation of
HSP70 due to knockdown of HSC70 fails to improve infectious
virion assembly and that simultaneous knockdown of HSP70 and
HSC70 leads to a similar decrease in viral translation as knock-
down of HSP70 alone further supporting the distinct roles that
HSP70 and HSC70 play in the viral life cycle. We are currently
investigating the NS5A/HSC70 interaction biochemically to iden-
tify the precise site(s) of interaction on both proteins. It may be
possible that HSC70 also utilizes the HBD hairpin to bind to NS5A.
We demonstrated that cyclization of the peptide improves antiviral
activity and HSP70 binding afﬁnity potentially by locking the peptide
in a more native hairpin-like structure and/or by rendering the
peptide less likely to be proteolytically cleaved. Furthermore, cycliza-
tion of the peptide signiﬁcantly decreases the alpha-helical contribu-
tions to the peptide secondary structure which is only observed in the
linearized peptide (HCV15R). In addition, we showed that the length
of the cyclizing linker is also important for its HSP70 binding afﬁnity
and for the function of the peptide to block virus production.
We hypothesized that the amino acid residues within the HBD
hairpin that are critical for the NS5A/HSP70 interaction should
Fig. 4. Molecular simulation of the HCV3 secondary structure. (A) Root Mean Square Deviation (RMSD) of the c-alpha backbone for HCV as a function of simulation time.
(B) Evolution of HCV3 secondary structure as a function of simulation time in aqueous periodic solvent box. (C) Residue speciﬁc assignments for HCV3 derived from FTIR
measurements of isotopically enhanced peptides and reﬁned by constrained molecular dynamics in aqueous buffer. Residues in blue typeface identify those labeled with 13C
at their carbonyl atoms. Conformational codes are as follows: r¼random–disordered structures; p¼parallel beta-sheet; and t¼turn conformations.
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most likely be conserved, and sequence comparison conﬁrmed the
existence of ﬁve conserved residues in the hairpin: Phe171, Val173,
Gly174, Leu175, and Tyr178. Analysis of the previously reported crystal
structure of dimeric NS5A domain I (Tellinghuisen et al., 2005) readily
revealed that Phe171, Val173, and Tyr178 occur on one side of the
plane of the hairpin beta-sheets suggesting that they could form a
binding surface with HSP70. In addition, the crystal structure also
shows the HBD and these three residues to be on the surface of the
dimer and exposed supporting their role as the NS5A/HSP70 binding
interface. In an alternate crystal structure of dimeric NS5A domain I
(Love et al., 2009), the two subunits appear as more compact closing
the proposed RNA binding cleft (Fig. 6). In this structure, while the two
HBD moieties appear to be still exposed, their location changes from
the side of the molecule to the bottom (Fig. 6). It is possible that the
former crystal structure provides for a better conformation for the
HBD to bind HSP70. Nevertheless, NS5A likely needs to undergo a
conformational change to allow HBD to form a tight binding interface
with HSP70, and this may be possible in both crystal structure
conformations.
To verify that these three conserved residues are involved in
the NS5A/HSP70 interaction, we substituted them with artiﬁcial
amino acids with large hydrophobic side chains. Substitutions at
Phe171 and Val173 improved the antiviral activity and binding
afﬁnity of the peptide, whereas substitution of Tyr178 had the
opposite effect. This is expected as tyrosine is a polar amino acid.
In addition substitution of the other non-conserved amino acids
within the hairpin did not affect cellular entry, antiviral activity,
and binding afﬁnity of the peptide. Thus, we conclude that the
binding of NS5A with HSP70 is mediated by these three conserved
amino acids within the C34 hairpin.
To conﬁrm our structural predictions of the peptide in aqueous
environments, we performed FTIR spectroscopy on the majority of
the peptides generated and observed that all peptides primarily
consist of beta-sheets and beta-turns consistent with the crystal
structure of the hairpin in the NS5A domain I (Tellinghuisen et al.,
2005). Alpha-helical contributions were minor except for the
linearized HCV15R peptide which also shows signiﬁcantly reduced
antiviral activity and HSP70 binding afﬁnity. FTIR spectroscopy
also indicated the existence of turn element in the peptide
consistent with our analysis of the crystal structures. Furthermore,
13C-enhanced spectroscopy of the HCV3 peptide clearly demon-
strated that Gly174 and Leu175 form a turn element between the
two beta-sheets of the hairpin conﬁrming our original predictions.
Molecular simulation of the HCV3 FTIR spectral analyses further
conﬁrmed the existence of all the predicted elements of the
peptide secondary structure including the N and C terminal
beta-sheets ﬂanking a beta-turn.
Thus, we have conﬁrmed the antiviral activity of a number of
HIPs that bind HSP70 and block the NS5A/HSP70 interaction.
Considering that most available therapeutic agents target the viral
proteins and induce the generation of resistant viral strains, HIPs
may serve as a potential new class of therapeutics for HCV
infection by targeting the host HSP70 as opposed to viral proteins
in order to minimize the development of resistance. Our data
indicates that the antiviral activity of HIPs is comparable to that of
sofosbuvir and ledipasvir in the HCVcc system (Lawitz et al., 2012;
Soﬁa et al., 2010). In combination with DAAs, HIPs may further be
able to dispense with the need for PEG-IFN and RBV that are
currently utilized in combination therapies. Further, insight pro-
vided here may also allow for development of therapies for others
viruses that utilize HSP70 recruitment.
Materials and methods
Plasmid constructs
NS5A domain I was cloned in the pET-28b plasmid (Novagen,
69865-3). The HCV IRES reporter plasmid has been previously
described (Gonzalez et al., 2009). An intra-genotype 2 chimeric
monocistronic reporter virus pNRLFC based on pJ6/JFH-C parental
virus has been described previously (Arumugaswami et al., 2008).
Fig. 5. Structure of HCV3 in aqueous buffer. (A) The HCV3 beta-sheet domains are
in ribbon-arrow format; Arg4–Glu9 ion pair is in stick format; and the disulﬁde
linkage between Cys1 and Cys13 is indicated by yellow stick connectivity.
(B) Crystal structure of HBD (Tellinghuisen et al., 2005) displayed in the same
orientation as the HCV3 peptide in panel A.
Fig. 6. Schematic representation of the previously reported alternate crystal
structure of dimeric NS5A domain I (Love et al., 2009). The HBD hairpins are
highlighted in red. The side chains of the four conserved residues (Phe171, Val173,
Leu175, and Tyr178) are also shown.
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For the current study, we have used a chemically synthesized
plasmid pFNX-RLuc (having similar sequences to pNRLFC) for
construction of recombinant virus.
Peptide synthesis and characterization
Peptides were synthesized by the solid phase method using a
CEM Liberty automatic microwave peptide synthesizer (CEM Cor-
poration), applying 9-ﬂuorenylmethyloxycarbonyl (Fmoc) chemis-
try (Fields and Noble, 1990) and standard, commercially available
amino acid derivatives and reagents (EMD Biosciences and Chem-
Impex International). Rink Amide MBHA resin (EMD Biosciences)
was used as a solid support. Peptides were cleaved from resin using
modiﬁed reagent K (TFA 94% (v/v); phenol, 2% (w/v); water, 2% (v/
v); TIS, 1% (v/v); EDT, 1% (v/v); 2 h) and precipitated by addition of
ice-cold diethyl ether. Reduced peptides were puriﬁed by prepara-
tive reverse-phase high performance liquid chromatography (RP-
HPLC) and their purity evaluated by matrix-assisted laser deso-
rption ionization spectrometry (MALDI-MS) as well as by analytical
RP-HPLC). Disulﬁde bond formation: Peptides were dissolved at a
ﬁnal concentration of 0.25 mg/ml in 50% DMSO:H2O and stirred
overnight at room temperature. Subsequently peptides were lyo-
philized and re-puriﬁed on a preparative C18 SymmetryShield™
RP-HPLC column to 495% homogeneity. Their purity was evaluated
by MALDI-MS as well as by analytical RP-HPLC. Analytical RP-HPLC:
Analytical RP-HPLC was performed on a Varian ProStar 210 HPLC
system equipped with ProStar 325 Dual Wavelength UV–vis detec-
tor with wavelengths set at 220 nm and 280 nm (Varian Inc.).
Mobile phases consisted of solvent A, 0.1% TFA in water, and solvent
B, 0.1% TFA in acetonitrile. Analyses of peptides were performed
with an analytical reversed-phase C18 SymmetryShield™ RP18 col-
umn, 4.6250 mm2, 5 μm (Waters Corp.) applying linear gradient
of solvent B from 0% to 100% over 100 min (ﬂow rate: 1 ml/min).
Cell culture
The cell line huh-7.5 was maintained in a humidiﬁed atmo-
sphere containing 5% CO2 at 37 1C in Dulbecco's Modiﬁed Eagle
Medium (Mediatech, 10-013-CM) supplemented with 10% fetal
bovine serum (Omega Scientiﬁc, FB-01) and 2 mM L-Gln (Life
Technologies, 25030). Huh-7.5 cells were a kind gift from Charles
Rice (The Rockefeller University, New York, NY).
Cell viability
Cell viability was determined using MTT Cell Proliferation assay
(ATCC, 30-1010K) according to manufacturer's instructions.
Infectious virus production
pFNX-RLuc was in vitro transcribed, and the puriﬁed RNA was
electroporated into huh-7.5 cells to generate infectious viral
supernatant as previously described (Arumugaswami et al., 2008).
Viral assays
The HCV reporter virus was utilized as described previously
(Khachatoorian et al., 2012a). All infection assays were performed
with a viral titer of 103 focus forming units and a multiplicity of
infection (MOI) of 0.1. Intracellular virus production: Huh-7.5 cells
were infected for 3 h at which point the medium was replaced,
indicated peptides were added, and infection was allowed to
proceed. Cells were harvested 48 h later, and luciferase activity
was measured using the Renilla Luciferase Assay System (Promega,
E2820).
Production and puriﬁcation of recombinant proteins
NS5A domain I was expressed and puriﬁed as described
previously (Wheatley et al., 2013). Brieﬂy, protein expression was
induced with 1 mM IPTG in BL21(DE3) Escherichia coli cells,
shaking at 250 rpm, for 5 h at 37 1C. Cells were centrifuged for
5 min at 6000 rpm and stored at 20 1C. Cells were resuspended
in 50 mM Tris–HCl pH 7.6, 300 mM NaCl, and 20 mM imidazole,
with Protease Inhibitor Cocktail (Sigma-Aldrich, P8849-5ml) and
lysed by sonication. Cells were spun down in a rotor SS-34 at
16,500 rpm for 30 min, ﬁltered through a 0.2 μm ﬁlter, and applied
to a Hi-trap Nickel column by a syringe at room temperature.
Proteins were eluted in one step with 50 mM Tris–HCl pH 7.6,
300 mM NaCl, and 400 mM imidazole.
Surface plasmon resonance (SPR)
Binding studies were performed on a Biacore 3000 instrument
(Biacore AB, Uppsala, Sweden). Proteins were immobilized on CM5
sensor chips by amine coupling. The solution phase analytes were
dissolved in HBS-EP buffer, which contained 0.15 M NaCl, 10 mM
HEPES, pH 7.4, 3 mM EDTA, and 0.005% polysorbate 20. The
solutions traversed the sensors at a ﬂow rate of 50 ml/min. Costar
low-retention polypropylene tubes (Corning, 3207) were used
throughout. Binding results were expressed in resonance units.
Kinetics and dissociation constants were analyzed and calculated
with BIAevaluation Software Version 4.1.
Fourier transform infrared (FTIR) spectroscopy
Infrared spectra were recorded at 25 1C using a Bruker Vector 22™
FTIR spectrometer with a deuterated triglycine sulfate (DTGS) detector,
and averaged over 256 scans at a gain of 4 with a resolution of 2 cm1.
Peptide samples were initially freeze-dried several times from 10mM
HCl in D2O to remove any interfering counterions and residual H2O.
Solution spectra of peptides were made in deuterated 10mM phos-
phate buffer, pD 5.6 (pD¼pHþ0.4). The spectra were acquired at a
peptide concentration of 2 mM in deuterium buffer using a tempera-
ture controlled, demountable liquid cell with calcium ﬂuoride win-
dows ﬁtted with a 50 μm thick Mylar spacer (Harrick Scientiﬁc,
Pleasantville, NY). The relative proportions of α-helix, turn, β-sheet,
and disordered conformations of solution and multilayer IR spectra
were determined by Fourier self-deconvolution for band narrowing
and area calculations of component peaks of the FTIR spectra using
curve-ﬁtting software supplied by Galactic Software (GRAMS/AI,
version 8.0; Thermo Electron Corp., Waltham, MA). The frequency
limits for the different structures were α-helix (1662–1645 cm1),
β-sheet (1637–1613 and 1710–1682 cm1), turns (1682–1662 cm1),
and disordered or random (1650–1637 cm1) (Byler and Susi, 1986).
Molecular Structure Simulation of HCV3 in Aqueous Solution
A starting structure for the HCV3 peptide amino acid sequence
was approximated by using Hyperchem 8.0 (http://www.hyper.com)
to template the backbone structure of the beta-hairpin conformation
that was derived from the homologous segment of the crystal
structure of NS5A domain I (PDB 1ZH1, residues (173–184) (Telling-
huisen et al., 2005). This preliminary structure was placed in a
periodic 56 Å3 box of TIP4P water, and the ensemble was neutralized
with counterions to simulate the environment used for the FTIR
isotope enhanced experimental measurements. The peptide in the
solution box was conjugate-gradient minimized using the Polak–
Ribiere approach implemented in Hyperchem. This minimized HCV3
aqueous ensemble was then ported to the Gromacs program suite,
version 4.5.5 (http://www.gromacs.org), and subjected to the steepest
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descent method using the Amber03 force ﬁeld option (Hess et al.,
2008).
The steepest descent minimized system was further subjected to
40 ps of pre-run molecular dynamics at 300 K to allow the solvent to
equilibrate while restraining the peptide. After pre-run solvent
equilibration the peptide structure was further reﬁned by 300 ns
of MD simulation at 300 K with residue speciﬁc constraints based on
FTIR isotope enhanced experimental observations. The Berendsen
protocol was used for temperature and pressure coupling and the
Particle Mesh Ewald method was employed for evaluating long-
range electrostatic interactions. The time-dependent evolution of
the secondary structure (analyzed using the DSSP criteria (Kabsch
and Sander, 1983)) for the peptide in the water environment
indicated when equilibrium was reached. Molecular model illustra-
tions were rendered using PyMOL v0.99 (http://www.pymol.org).
Crystal structure analysis
The illustrations for crystal structures 1ZH1 and 3FQQ were
rendered using UCSF Chimera v1.9 (http://www.cgl.ucsf.edu/chimera).
Statistical analysis
Error bars reﬂect the standard deviation. P values were deter-
mined by Student t test. All viral assays were done with six
biological replicates for each individual assay.
IC50 calculation
IC50 values were calculated based on the formula derived from
a third degree polynomial curve ﬁt in Microsoft™ Excel™.
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